A Phase 1b, Multicenter, Open Label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant
Latest Information Update: 20 May 2025
At a glance
- Drugs Tegoprubart (Primary) ; Antithymocyte globulin; Mycophenolate mofetil; Steroids
- Indications Renal transplant rejection
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eledon Pharmaceuticals
Most Recent Events
- 14 May 2025 According to an Eledon Pharmaceuticals, updated interim clinical data anticipated in August 2025.
- 20 Mar 2025 According to an Eledon Pharmaceuticals, interim clinical data from this trial evaluating expected in Summer 2025.
- 07 Feb 2025 According to an Eledon Pharmaceuticals media release, company to report results form this trial this summer.